Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Center Ombudsman To Establish Tracking System For Disputes

This article was originally published in The Gray Sheet

Executive Summary

One of the top priorities for newly appointed FDA Center for Devices and Radiological Health Ombudsman and Quality Assurance Manager Les Weinstein will be establishing a tracking system for ongoing dispute resolution cases.

You may also be interested in...



Grassroots Task Force Looks To Guide Firms Making Complaints To CDRH

A Medical Device Industry Initiative Grassroots Taskforce subcommittee is considering whether to develop guidelines for manufacturers that feel they have received unequal treatment by the FDA's Center for Devices and Radiological Health.

Grassroots Task Force Looks To Guide Firms Making Complaints To CDRH

A Medical Device Industry Initiative Grassroots Taskforce subcommittee is considering whether to develop guidelines for manufacturers that feel they have received unequal treatment by the FDA's Center for Devices and Radiological Health.

LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort

Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel